UNH
UnitedHealth Group Incorporated
UNH has the edge over VVOS overall, supported by lower modeled downside and stronger fundamentals.
VVOS
Vivos Therapeutics, Inc.
VVOS trails on the overall score without a compensating advantage in the available component scores.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
VVOS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
VVOS's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
VVOS PE Valuation
VVOS has no meaningful PE right now: it lost money over the past year.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
VVOS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect VVOS's losses to grow, with revenue growing.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the stronger earnings trend. Trailing diluted EPS is down 8.5% for UNH versus VVOS down 117%.
VVOS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$10.12 | +$2.88 |
| Q2 2024 | -$11.47 | +$6.28 |
| Q1 2024 | -$15.37 | +$6.13 |
| Q4 2023 | -$15.49 | +$10.51 |
| Q3 2023 | -$13.00 | +$16.00 |
| Q2 2023 | -$17.75 | +$11.25 |
| Q1 2023 | -$21.50 | +$4.00 |
| Q4 2022 | -$26.00 | -$2.00 |
VVOS is still losing money, but far less than before: $1.90 per share over the past year, against $29.00 at its worst in mid-2022.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over VVOS on profitability, with a higher operating margin.
VVOS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.2M | +35% |
| Q1 2026 | $5.1M | +70% |
| Q4 2025 | $3.8M | +3.4% |
| Q3 2025 | $6.8M | +76% |
| Q2 2025 | $3.8M | -5.8% |
| Q1 2025 | $3M | -12% |
| Q4 2024 | $3.7M | +14% |
| Q3 2024 | $3.9M | +17% |
VVOS's revenue has grown year over year for four quarters in a row: $5M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -94% | +34 points |
| Q1 2026 | -129% | +1.2 points |
| Q4 2025 | -167% | -91 points |
| Q3 2025 | -70% | -1.3 points |
| Q2 2025 | -127% | -80 points |
| Q1 2025 | -130% | -19 points |
| Q4 2024 | -76% | +56 points |
| Q3 2024 | -69% | +37 points |
VVOS's operating margin was −94% last quarter, up 34 points from the same quarter a year ago.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over VVOS on cash generation, producing positive trailing cash flow while its opponent burns cash.
VVOS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.6M | +$701K |
| Q1 2026 | -$6M | -$2.1M |
| Q4 2025 | -$5.3M | -$2.2M |
| Q3 2025 | -$4.1M | +$301K |
| Q2 2025 | -$4.3M | -$1.2M |
| Q1 2025 | -$3.9M | -$1.3M |
| Q4 2024 | -$3.1M | -$192K |
| Q3 2024 | -$4.4M | -$1.4M |
VVOS has burned cash in almost every quarter: −$19M over the past year, against −$16M the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over VVOS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
VVOS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +3M shares |
| 1 year | +106% | +9.1M shares |
| 3 years | +1982% | +16.8M shares |
| 5 years | +3457% | +17.2M shares |
VVOS has 18M diluted shares, up 106% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2M |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $150,000 |
| Q4 2019 | — |
| Q3 2019 | $50,000 |
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
VVOS Net Leverage
VVOS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
VVOS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.8 | Oversold |
| Stochastic | 1.3 | Oversold |
VVOS's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
VVOS PE vs Healthcare Sector
VVOS has no meaningful PE right now: it lost money over the past year.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over VVOS on trend strength, trading above more of its moving averages.
VVOS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.13 | 23% below |
| 20 week MA | $0.24 | 58% below |
| 50 week MA | $0.88 | 89% below |
| 100 week MA | $2.22 | 95% below |
| 200 week MA | $4.63 | 98% below |
VVOS is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over VVOS on returns for 2026, with the stronger performance.
VVOS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $224.8 | $184.5 | -18% |
| 2021 | $184.5 | $68.5 | -63% |
| 2022 | $68.5 | $11.9 | -83% |
| 2023 | $11.9 | $12.4 | +4.3% |
| 2024 | $12.4 | $4.65 | -63% |
| 2025 | $4.65 | $2.03 | -56% |
| 2026 YTD | $2.03 | $0.10 | -95% |
VVOS has finished lower in five of the last six years. It's down 95% so far in 2026.